首頁 > 市場調查報告書 > 醫療設備

導管泌尿科

市場調查報告書

商品編碼

1732187

輸尿管支架市場：依產品、材料、應用、最終用戶、地區，2026年至2032年

Ureteral Stents Market By Product, Material, By Application, By End-User (Hospitals, Clinics, Ambulatory Surgical Centers ), & Region For 2026-2032

出版日期: 2025年04月29日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026-2032年輸尿管支架市場評估

泌尿系統疾病（尤其是腎結石）的發生率不斷上升，以及使用微創技術改善患者康復和舒適度，推動輸尿管支架市場向前發展。據 Verified Market Research 分析師表示，輸尿管支架市場規模預計將在2024年下降至約 5.4854億美元，並在預測期內達到 8.4374億美元的估值。

支架材料和設計的技術改進，尤其是靈活和生物相容性的選擇，推動市場需求。這將有助於市場在2026年至2032年期間以 6.1%的年複合成長率成長。

輸尿管支架市場定義/概述

輸尿管支架是一種細而柔軟的管子，插入輸尿管可幫助將尿液從腎臟排放膀胱，尤其是在尿液正常流動受阻的情況下。這些支架通常用於治療腎結石、因腫瘤或狹窄引起的輸尿管阻塞以及因腫脹或組織修復引起的術後阻塞。輸尿管支架是泌尿系統治療的重要組成部分，因為它可以保持輸尿管通暢，確保最佳腎功能，同時緩解與泌尿道阻塞相關的症狀。

哪些因素推動了輸尿管支架市場需求的激增？

腎結石發生率的不斷上升是輸尿管支架市場的主要驅動力。美國美國糖尿病、消化和腎臟疾病研究所（NIDDK）估計，美國約有 11%的男性和 9%的女性患有腎結石。 NIDDK 也指出，美國腎結石的發生率已從 1970年代末的3.8%上升至2000年代末的8.8%。盛行率的增加使得需要進行更多的輸尿管支架手術，進而推動市場擴張。

全球人口老化推動了對輸尿管支架的需求，因為老年人更容易出現泌尿器官系統問題。世界衛生組織預測，到2030年，六分之一的人將超過60歲。預計到2050年，這一數字將上升到五分之一。從統計資料來看，人口將從2020年的10億增加到2030年的14億，再到2050年的21億。老年人口更容易罹患需要輸尿管支架的疾病，刺激市場擴張。

此外，輸尿管支架設計和材料的不斷進步日益擴大其應用範圍，同時改善患者的治療效果。例如，美國食品藥物管理局（FDA）積極核准新的輸尿管支架技術。牛頓引流器輸尿管導管用於從腎臟排放結石碎片，於2019年被 FDA 指定為突破性設備。這些改進擴大了輸尿管支架的應用範圍，並推動了市場成長。根據FDA設備和放射健康中心（CDRH）的資料，2009年至2019年間，創新設備的核准數量增加了25％，這表明醫療設備，尤其是輸尿管支架的創新趨勢。

哪些因素阻礙了輸尿管支架市場的成長？

藥物釋放型和生物分解性支架是突破性技術的例子，它們有可能提供更好的治療效果，但其高昂的成本使患者和醫療保健專業人員無法承受，尤其是在資源貧乏的地區。這種經濟負擔阻礙了人們採用這些先進的解決方案，導致人們依賴無法提供相同好處的廉價替代方案。

輸尿管支架留置後出現問題的風險是另一個挑戰。患者可能會出現支架移位、卡住和尿道感染等併發症，需要額外的醫療。這些發現不僅影響患者的治療結果，而且還增加了醫療支出和資源使用，使得醫生不願意提案將支架置入作為第一線治療方法。

The rising frequency of urological disorders, especially kidney stones, and the use of minimally invasive techniques that improve patient recovery and comfort, are driving the Ureteral Stents Market forward. According to the analyst from Verified Market Research, the Ureteral Stents Market is estimated to reach a valuation of USD 843.74 Million over the forecast subjugating around USD 548.54 Million valued in 2024.

Technological improvements in stent materials and designs, particularly flexible and biocompatible choices, are driving up market demand. It enables the market to grow at a CAGR of 6.1% from 2026 to 2032.

Ureteral Stents Market: Definition/ Overview

A ureteral stent is a thin, flexible tube put into the ureter to aid in the drainage of urine from the kidney to the bladder, especially when normal urine flow is impeded. These stents are widely used to treat kidney stones, ureteral obstructions caused by tumors or strictures, and post-surgical blockages due to swelling or tissue repair. Ureteral stents are an important component in urological therapies because they maintain the ureter open and assist ensure optimal kidney function while also alleviating symptoms associated with urinary obstructions.

What are the Factors that Surge the Demand for the Ureteral Stents Market?

The increased occurrence of kidney stones is a major driver of the Ureteral Stents Market. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) estimates that kidney stones affect approximately 11% of men and 9% of women in the United States. The NIDDK also notes that the incidence of kidney stones in the United States has risen from 3.8% in the late 1970s to 8.8% in the late 2000s. This increasing prevalence needs more ureteral stent surgeries, which drives market expansion.

The global aging population is driving up demand for ureteral stents, as older persons are more prone to urological problems. The World Health Organization (WHO) predicts that by 2030, one in every six persons will be 60 or older. This number is predicted to rise to one in five by 2050. In statistics, this represents a rise from 1 billion in 2020 to 1.4 billion by 2030 and 2.1 billion by 2050. The elderly population is more vulnerable to disorders that necessitate ureteral stents, fueling market expansion.

Furthermore, continuous advancements in ureteral stent design and materials are broadening their uses while improving patient outcomes. For example, the United States Food and Drug Administration (FDA) has been actively approving novel ureteral stent technology. The Newton-Drainer Ureteral Catheter, which is meant to drain stone fragments from the kidney, was designated a Breakthrough Device by the FDA in 2019. Such improvements are expanding the use of ureteral stents and driving market expansion. According to the FDA's Center for Devices and Radiological Health (CDRH), the number of innovative device approvals increased by 25% between 2009 and 2019, demonstrating a trend toward innovation in medical devices, particularly ureteral stents.

What Factors Hinder the Growth of the Ureteral Stents Market?

Drug-eluting and biodegradable stents are examples of breakthroughs that hold out the potential for better outcomes, but their high cost puts patients and healthcare professionals out of reach, especially in areas with few resources. This financial burden discourages the adoption of these sophisticated solutions, resulting in a reliance on less expensive alternatives that do not provide the same benefits.

The risk of problems following the placing of a ureteral stent presents another difficulty. Patients develop complications such as stent migration, encrustation, and urinary tract infections, requiring extra medical treatments. These consequences not only have an impact on patient outcomes but also raise healthcare expenditures and resource use, making doctors hesitant to propose stenting as a first-line treatment option.

Category-Wise Acumens

How Does the Increasing Adoption of Double Pigtail Stents Drive the Market Growth?

According to VMR analysis, the double pigtail stent segment is estimated to hold the largest market share during the forecast period due to its high biocompatibility, which reduces the chance of unpleasant reactions and problems like infection or tissue irritation. This characteristic makes double pigtail stents the favored option among healthcare professionals, resulting in improved patient outcomes and higher satisfaction rates. Their design enables excellent drainage while decreasing the possibility of encrustation, which increases their attractiveness in clinical settings.

Double pigtail stents' flexibility and simplicity of insertion are also significant factors. Their unique form allows for smoother installation using less invasive techniques, making them easier to manage during treatments. This ease of use not only increases procedural efficiency but also reduces patient discomfort, prompting more healthcare practitioners to employ them for a variety of urological procedures.

Furthermore, the increasing prevalence of urological problems, such as kidney stones and urinary tract blockages, is driving demand for double pigtail stents. As these problems become more widespread, particularly in older populations, healthcare providers rely more on these stents to properly address urinary issues. The increasing prevalence of such illnesses confirms the market dominance of double pigtail stents, which are best adapted to resolving these issues.

How Does the High Prevalence of Kidney Stones Propel the Growth of the Ureteral Stents Market?

The kidney stone segment is estimated to dominate the Ureteral Stents Market during the forecast period due to the high occurrence of kidney stones. Kidney stones impact a large proportion of the global population, creating a growing demand for effective treatment alternatives. Ureteral stents are frequently utilized to relieve obstruction produced by these stones, maintaining correct urine flow and minimizing accompanying pain, emphasizing their critical role in addressing this problem.

Technological developments in stent design are also important for segment growth. Drug-eluting and biodegradable stents are examples of innovations that improve kidney stone treatment effectiveness, patient outcomes, and comfort. These developments not only make it easier to pass stones, but they also reduce complications, leading healthcare practitioners to select ureteral stents as the preferred technique for managing kidney stones.

Furthermore, the growing knowledge and accessibility of healthcare services help to drive the growth of the kidney stones segment. As more patients seek medical assistance for urological disorders, understanding of kidney stone management has grown. This trend promotes timely treatments with ureteral stents, consolidating their position as the preferred method for treating kidney stone-related blockages.

Country/Region-wise Acumens

How Does the High Prevalence of Urological Disorders Influence Growth in North America?

According to VMR analyst, North America is estimated to dominate the Ureteral Stents Market during the forecast period. Urological problems are common in North America, especially in the United States, and are frequently treated using ureteral stents. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), around 11% of men and 6% of women in the United States will have kidney stones at some point in their life. Also, the American Urological Association says that benign prostatic hyperplasia (BPH) affects approximately 50% of men aged 51 to 60 and up to 90% of men over the age of 80, with many requiring ureteral stents as part of their treatment.

Furthermore, the expanding geriatric population in North America is a significant driver of the Ureteral Stents Market, as older persons are more prone to urological problems. According to the United States Census Bureau, by 2030, all baby boomers will be above the age of 65, increasing the number of the elderly population to one in every five individuals. Specifically, the number of Americans aged 65 and over is expected to increase from 52 million in 2018 to 95 million by 2060. This demographic trend is projected to boost demand for urological procedures, such as ureteral stents.

What Factors Contribute to the Potential Opportunities in the Asia Pacific Region?

The Asia Pacific region is estimated to exhibit the highest growth within the Ureteral Stents Market during the forecast period. The Asia Pacific region is experiencing considerable growth in the older population, which is particularly vulnerable to urological illnesses that require ureteral stents. According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), the region's elder population (aged 65 and more) is predicted to more than double from 535 million in 2015 to around 1.3 billion by 2050. In countries such as Japan, the proportion of people aged 65 and more is expected to reach 38% by 2050. This demographic trend is expected to increase demand for ureteral stents and other urological treatments.

Furthermore, the Asia Pacific region is experiencing an increase in urological problems, particularly kidney stones. According to research published in the Asian Journal of Urology, the prevalence of kidney stone illness in China has risen from 4% in the 1980s to 6.4% in the 2000s. According to India's Department of Health & Family Welfare's Annual Report 2020-2021, urolithiasis (kidney stones) is growing more common, with a prevalence rate of 12% in the adult population. This increased disease burden is likely to drive up demand for ureteral stents in the region.

Competitive Landscape

The Ureteral Stents Market has a broad set of participants, including both large global organizations and smaller, specialized firms. This fragmentation encourages innovation, as businesses focus more on developing new stent technologies, such as drug-eluting and biodegradable choices, to improve patient outcomes and satisfaction.

Some of the prominent players operating in the Ureteral Stents Market include:

Boston Scientific Corporation, Coloplast Ltd., Allium Medical Solutions Ltd., Becton, Dickinson and Company, Cook Group Incorporated, Braun Melsungen AG, Bard, Teleflex Incorporated, Olympus Corporation, and Biomerics.

Latest Developments

In May 2022, University Hospitals invented a novel stent developed by Ureteral Stent Co. Lee Ponsky, MD, and obtained FDA Clearance. Ureteral stents facilitate urine flow from the kidney to the bladder, preventing kidney damage caused by kidney stones, strictures, or ureter edema.

In April 2022, Boston Scientific received a bronze Edison Award in the Science & Medical category for its Tria Ureteral Stent. This stent is the first to use proprietary surface technology to prevent the accumulation of calcium and magnesium salt deposits in urine.

1 INTRODUCTION OF GLOBAL URETERAL STENTS MARKET

1.1 Introduction of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL URETERAL STENTS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL URETERAL STENTS MARKET, BY PRODUCT

5.1 Overview
5.2 Open End Stents
5.3 Double J-Stents
5.4 Closed End Stents
5.5 Multiloop Stents

6 GLOBAL URETERAL STENTS MARKET, BY MATERIAL

6.1 Overview
6.2 Metallic Stents
6.3 Polymer Stents

7 GLOBAL URETERAL STENTS MARKET, BY APPLICATION

7.1 Overview
7.2 Kidney Stones
7.3 Kidney Transplantation
7.4 Tumors
7.5 Urinary Incontinence
7.6 Others

8 GLOBAL URETERAL STENTS MARKET, BY END-USER

8.1 Overview
8.2 Hospitals
8.3 Clinics
8.4 Ambulatory Surgical Centers (ASCs)

9 GLOBAL URETERAL STENTS MARKET, BY GEOGRAPHY

9.1 Overview
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 U.K.
- 9.3.3 France
- 9.3.4 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Rest of Asia Pacific
9.5 Rest of the World
- 9.5.1 Latin America
- 9.5.2 Middle East and Africa

10 GLOBAL URETERAL STENTS MARKET COMPETITIVE LANDSCAPE

10.1 Overview
10.2 Company Market Ranking
10.3 Key Development Strategies

11 COMPANY PROFILES

11.1 Boston Scientific Corporation
- 11.1.1 Overview
- 11.1.2 Financial Performance
- 11.1.3 Product Outlook
- 11.1.4 Key Developments
11.2 Coloplast Ltd.
- 11.2.1 Overview
- 11.2.2 Financial Performance
- 11.2.3 Product Outlook
- 11.2.4 Key Developments
11.3 Allium Medical Solutions Ltd.
- 11.3.1 Overview
- 11.3.2 Financial Performance
- 11.3.3 Product Outlook
- 11.3.4 Key Developments
11.4 Becton, Dickinson and Company
- 11.4.1 Overview
- 11.4.2 Financial Performance
- 11.4.3 Product Outlook
- 11.4.4 Key Developments
11.5 Cook Group Incorporated
- 11.5.1 Overview
- 11.5.2 Financial Performance
- 11.5.3 Product Outlook
- 11.5.4 Key Developments
11.6 Braun Melsungen AG
- 11.6.1 Overview
- 11.6.2 Financial Performance
- 11.6.3 Product Outlook
- 11.6.4 Key Developments
11.7 R. Bard
- 11.7.1 Overview
- 11.7.2 Financial Performance
- 11.7.3 Product Outlook
- 11.7.4 Key Developments
11.8 Teleflex Incorporated
- 11.8.1 Overview
- 11.8.2 Financial Performance
- 11.8.3 Product Outlook
- 11.8.4 Key Developments
11.9 Olympus Corporation
- 11.9.1 Overview
- 11.9.2 Financial Performance
- 11.9.3 Product Outlook
- 11.9.4 Key Developments
11.10 Biomerics
- 11.10.1 Overview
- 11.10.2 Financial Performance
- 11.10.3 Product Outlook
- 11.10.4 Key Developments